Amedisys (AMED) Upgraded at Zacks Investment Research
Amedisys (NASDAQ:AMED) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm presently has a $57.00 price objective on the health services provider’s stock. Zacks Investment Research‘s target price indicates a potential upside of 1.50% from the stock’s previous close.
According to Zacks, “Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”
Other research analysts have also issued research reports about the company. Mizuho reissued a “buy” rating and set a $65.00 price objective (up previously from $55.00) on shares of Amedisys in a report on Wednesday, November 8th. Royal Bank of Canada reissued a “hold” rating on shares of Amedisys in a report on Monday, October 23rd. BidaskClub lowered Amedisys from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. William Blair reaffirmed an “outperform” rating on shares of Amedisys in a research note on Tuesday, November 21st. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $70.00 target price on shares of Amedisys in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $60.64.
Institutional investors and hedge funds have recently modified their holdings of the business. LS Investment Advisors LLC boosted its stake in Amedisys by 233.1% in the fourth quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock worth $188,000 after buying an additional 2,494 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in shares of Amedisys during the third quarter valued at approximately $205,000. Amalgamated Bank purchased a new stake in shares of Amedisys during the second quarter valued at approximately $246,000. Janus Henderson Group PLC purchased a new stake in shares of Amedisys during the second quarter valued at approximately $278,000. Finally, NorthCoast Asset Management LLC purchased a new stake in shares of Amedisys during the third quarter valued at approximately $262,000. 94.97% of the stock is owned by institutional investors and hedge funds.
WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/08/amedisys-amed-upgraded-at-zacks-investment-research-2.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.